Three giants beat Wall Street expectations, raise stakes for 2025, and hint at industry-shaping breakthroughs.
Wall Street just got a triple shock from the MedTech arena.
Johnson & Johnson, Abbott, and Boston Scientific all posted second-quarter earnings that beat analyst expectations—despite economic headwinds, regulatory shifts, and global market pressure. Together, they signal renewed momentum in the $600B+ medical technology sector.
Johnson & Johnson: Betting Big on Robotics
- Q2 Revenue: $23.7B (+5.8%)
- Profit: $5.5B (+18.2%)
- MedTech Revenue: $8.5B (+7.3%)
- Outlook Raised: New FY25 EPS guidance of $10.80–$10.90
- Big Move: Ottava surgical robot set for FDA submission in FY26
CEO Joaquin Duato says J&J is primed for “game-changing approvals” in surgery and cardiovascular. The company’s surgical robotics play could rattle Intuitive Surgical’s long-standing dominance.
Abbott: Strong Devices, Weaker Guidance
- Q2 Revenue: $11.14B (+7.3%)
- Profit: $1.8B (+36.6%)
- CGM Sales (FreeStyle Libre): $1.9B (+21.4%)
- Medical Devices Growth: +13.4%
- Adjusted EPS Guidance: Narrowed to $5.10–$5.20
Despite beating estimates, Abbott’s stock dipped 8% due to trimmed guidance amid federal HIV funding cuts. Still, analysts remain bullish, pointing to “premium growth” across diabetes and heart segments.
Boston Scientific: The Quarter’s Breakout Star
- Q2 Revenue: $5.06B (+22.8%)
- Profit: $797M (2x YoY)
- Cardiology Growth: +29.3%
- EPS Guidance Raised: $2.95–$2.99 (prev. $2.87–$2.94)
- Product Wins: Farapulse PFA and Watchman gain FDA nods
With fresh approvals, major acquisitions, and standout growth in Urology and Cardiology, Boston Scientific continues to outperform even “sky-high expectations,” say analysts.
These Q2 earnings aren’t just wins on paper—they’re strong indicators of innovation cycles accelerating in robotics, cardiac care, diabetes, and surgical technology. With J&J gearing up for Ottava’s debut and Boston Scientific doubling profits, the MedTech arms race is on.
Follow MEDWIRE.AI for MedTech earnings insights and market-moving trends.
